GH Research

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted for 2026 5 January 2026 -- Dublin, Republic of Ireland -- GH Research PLC, a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients...
Joshua Dawson House Dawson Street Dublin 2, D02 RY95 Ireland